We've rebranded!

HT-ADME is now NE-ADME (New Era of ADME & Beyond) 2022 Conference!

Please visit us at: 


More Details Coming Soon! 


Plenary Speaker for 2021


Marcel Hop, PhD, Vice President, DMPK, Genentech

Influencing Design with in silico ADME Models


Kathy Giacomini, PhD, Professor, Bioengineering, Co-Director UCSF-Stanford Center of Excellence in Regulatory Sciences and Innovation, School of Pharmacy, UCSF

High Throughput Screening and Real World Biomarkers to Predict Drug-Drug and Drug-Nutrient Interactions: Implications to poly pharmacy associated with COVID


Yurong Lai, Gilead, PhD, FAAPS, Sr. Director, Drug Metabolism, Gilead Sciences

Title TBA - ADME data on Remdesivir/treatment efficacy


David Rodrigues, PhD, Senior Scientific Director, Head of Transporter Sciences Group, Pfizer

Liquid Biopsy in ADME: Where are We Now and Where are We Going?


Speakers Confirmed for 2021


Dallas Bednarczyk, PhD, Senior Principal Scientist, Novartis Institutes for Biomedical Research

The Impact of Ion Trapping on the Cellular Accumulation of Highly Permeable Low Molecular Weight Acidic Drugs


Bo Feng, PhD, Director, DMPK, Vertex Pharmaceuticals

Validation of PXB Chimeric Mice with Humanized Liver to Predict Human Liver-to-Plasma Kpuu of OATP1B1 Substrates


Na Li, PhD, Senior Research Scientist II, C4 Therapeutics

Improved IVIVE for Hepatic Clearance Prediction: The Impact of Albumin on Hepatic Uptake


Iain Martin, Vice President, DMPK, Relay Therapeutics 

Unbound Volume of Distribution as a Foundational Parameter in Drug Design


Randy Miller, Senior Investigator, Merck

Unbound Volume of Distribution as a Foundational Parameter in Drug Design


Mark Milton, PhD, Ophthalmology Therapeutic Area Head, PK Sciences at Novartis Institutes for BioMedical Research (NIBR)

AAV Gene Therapies - New Opportunities for ADME Scientists


Xin Xu, PhD, Senior Scientist, National Center for Advancing Translational Sciences (NCATS), NIH

NCATS ADME Datasets and In Silico Models Derived from These Datasets



Albert Li, PhD, President & CEO at In Vitro ADMET Laboratories 

999Elite Cryopreserved Human Hepatocytes




Peter Tatrai, PhD, Senior Scientist, R&D, Solvo Biotechnology A Charles River  Company

Mechanistic Insights Into the Inhibitor Preincubation Effect


Beth Williamson, PhD, DMPK Project Representative, Early Oncology DMPK, AstraZeneca, UK

Quantitative and Qualitative Aspects of PROTAC Metabolism: Do they differ from small molecule?


Mark Wenlock, PhD, Physical Chemistry Team Leader @ Cyprotex 

High Throughput Physical Chemistry Assays: Advances and Application


Ismael Zamora, PhD, CFO @ Lead Molecular Design, S.L. 

HT-ADME: From Data to Knowledge. Generate Data to Feed AI Model Operation and Reach Optimal Compound Deisgn


Kenneth R. Brouwer, PhD, RPh, Vice President, Technologies-ADME-TOX @ BioIVT

Importance of Polarized Models for the Evaluation of Hepatic Transporter Based Drug Interactions 



Session Topics Proposed for 2021 include: 

New Modalities

New ADME Technologies


PBPK Modeling


Join our Linkedin Group:


Session I: ADME Prediction Tools for Old and New Therapeutic Modalities

Session II: Transporter-Mediated Drug Disposition

Session III: Bioanalysis of New Therapeutic Modalities

Sessin IV: New Clearance Prediction Models



Click here to register for the HT-ADME conference online.

HT-ADME 2021 will take place June 22-23, 2021

Virtual Event


The Boston Society

The Boston Society (R) is an internationally-recognized NON-PROFIT organization dedicated to bringing the best scientific ideas to industrial practice through focused, timely workshops and conferences. 501(c)3


Sign Up Today!

Privacy Policy